Introduction
This is an abridged version of the Surveillance of Bacterial Meningitis in Europe report 1999/2000. The following facts and figures were the most up to date available at the time of compiling this report. The full version of the forty-seven-page report contains further epidemiological data, sections on trends, a review of outbreaks and reports on countries outside of Europe; including the USA, Australia and New Zealand. If you are interested in the complete document contact us using the details at the end of this report.
For this report twenty-nine European countries and one region provided information on cases of meningococcal disease. Ten countries reported pneumococcal and/or H. influenzae meningitis case data.
The EU now separately funds surveillance of meningococcal disease in EU countries. It is however, working closely with us on the surveillance of meningococcal disease in Europe, so there is no waste of resources. Data collected by the EU surveillance feeds into our own database, with the consent of the countries involved.
All incidence rates are based on reported infections and are per 100,000 population per year unless otherwise stated. With a few exceptions, total numbers reported are likely to be incomplete. All incidence data have to be interpreted cautiously because of under reporting, especially where the rate is low. This report should be used to interpret trends rather than be used as an indicator of true incidences. EU surveillance of meningococcal disease. Most countries have given permission for their data to be passed on to us in the detailed format used by the project. Others send the data to us separately in a format suitable for them. The data is transferred into a corresponding Excel spreadsheet. This functions as a template where data can be initially checked for coding and format standardisation. This is then imported into a password protected "Core" Access database for permanent storage.
Selected data fields covering the required time period are then exported to a satellite "Reports" database where they can be temporarily stored for processing into reports without risk to the central data. Filter queries are used to further check and clean the data so that it can be exported as a set of standard Excel tables, as used in the quarterly reports, or an ad hoc Excel table designed as required.
Disease definitions are as follows:
Invasive meningococcal disease Covers all meningococcal infections causing symptoms other than carriers/throat infections. ICD-10 codes: A39.0 to A39.9 Septicaemia Covers the presence in the blood of meningococci and the symptoms of septicaemia. ICD-10 codes: A39.2 to A 39.4
Meningitis
Covers the presence in the CSF of meningococci and the symptoms of meningitis. ICD-10 code: A39.0 Both Evidence of both septicaemia and meningitis on the basis of clinical diagnosis and/or laboratory tests.
For laboratory cases the diagnosis was confirmed by laboratory methods, either culture or non-culture. Notifications were based on clinical presentation and may or may not be confirmed by laboratory methods. Most of the data presented here are based on laboratory reports.
Core Data Set
For figures comparing reporting periods a core of 16 countries which have reported all four quarters in each reporting period has been used. The countries are Austria, Belgium, the Czech Republic, England & Wales, France, Germany, Greece, Iceland, Israel, Netherlands, Norway, Republic of Ireland, Scotland, Slovak Republic, Slovenia and Spain. This was done to provide a data set that would give a more reliable representation of possible changes in the epidemiology of McD over time. It also allows some assessment of the reliability of the current reporting system.
3.
Results: Meningococcal Disease
Distribution, Incidence and Clinical Diagnosis
For the period July 1999 to June 2000, thirty countries from Europe contributed data. Twenty-nine European contributors reported a total of 8279 laboratory confirmed cases. For notifications, nine European contributors from the complete data set reported a total of 1333 cases. Twenty-five countries were eligible for inclusion in calculating an overall standardised incidence rate for Europe for laboratory confirmed cases. Four of the countries excluded provided only two quarters of data for the period covered by the report, and one only provided notifications. The countries included reported 8143 laboratory-confirmed cases of meningococcal disease, giving an overall age standardised incidence rate of 1.8. For the core data set the standardised incidence rate was 2.4. A total standardised incidence rate was also calculated for all the laboratory-confirmed cases. The incidence rate was 1.7, a little lower than either the complete or core data sets. 
Incidence -Notifications and Laboratory data

Clinical Diagnosis and Case Fatality Rate
The ratio of septicaemia to meningitis showed considerable variation between countries, which may be due to diagnostic convention or real differences. Overall, the clinical presentation was 40% meningitis alone, 41% septicaemia alone and 16% a combination of both. 1% (86 cases) were designated "meningitis/septicaemia not specified". Of the remaining cases, 2% (130 cases) had a stated clinical diagnosis. These included 13 cases of arthritis, 11 cases of conjunctivitis, 5 cases of otitis, and 3 cases of pneumonia, with the remaining cases designated "other". Nine cases recorded as purpura were re-coded as septicaemia. For laboratory confirmed data the case fatality rate for "meningitis only" was 6.1% (141 fatalities), for "septicaemia only" 7.6% (179 fatalities) and for cases of combined septicaemia and meningitis 6.5% (59 fatalities). The rate for those "not specified" was 1.2% and for "other" 8.5%. The overall CFR for laboratory confirmed cases was 6.9%.
Age
The age distribution shown by core data set countries (figure 1 and Table 2 ) was as expected, with the main peak in infancy. The secondary teenage peak was still present. From 1998/99 to 1999/2000 the incidence rate increased in most age groups. This increase ranged from 8% for 10 to 14 years to about 50% for 25 to 44 years. The increase in the 15-19 year olds was only 9% compared with an overall increase of 14%. Increases of 21% in incidence in those aged 1-11 months, and of 20% in 1-4 year olds are more important because of the large numbers in these age groups.
How Representative is the Complete Group?
The core group represents greater completeness and continuity of reporting. The overall incidence of meningococcal disease in the core group is possibly nearer the true incidence in Europe than the complete group. Nevertheless A comparison of the age distributions in the two sets of data can be used to assess how representative reports are from countries not in the core group. These show (figure 1) that the ratio of core/complete incidence rates in each age group is consistently 1.4 -1.5. The exceptions are those aged under 1 month (1.2) in which the complete group is slightly over represented (and this may be real), and 20 to 24 year olds (1.3) Thus although the incidence in the core-group countries is consistently higher, the age distributions are similar in the two groups. 
Case Fatality Rate
As in previous years the case fatality rate (CFR) increased with age (table 3 and Figure 3) . A J-shaped pattern was more prominent this year than in previous years. Case fatality rates have to be interpreted with caution. Overall, the outcome was reported in 49% of the cases (table 4) . The reported CFR for Europe in 1999/2000 was higher than in 1998/99, at 6.9% for the complete data and 7.0% for the core data set. For some countries only two quarters' data were provided. Between countries considerable variation was seen in the CFR. The rate where outcome was known varied from 3.5% in Russia Moscow, through 14.3% in Iceland and Latvia, to more than 20% in Germany. The rate was also higher than 20% in Estonia and Slovenia, though these are both countries with small numbers of cases. High case fatality rates may reflect better reporting of more severe cases, while very low rates may indicate that some deaths occurred after diagnosis was made and the case reported. 
Serogroups
Serogroup B and C disease together accounted for 95% of cases in Europe (table 5) , with serogroup B predominant (63% of grouped strains). The proportion of serogroup C isolated varied by country (tables 5 and 6). Countries with 40% serogroup C or higher included Iceland, Northern Ireland, Russia (Moscow), the Slovak Republic, Spain and Switzerland. Compared with 1998/99 this represents an important change for Spain and Switzerland. Countries with less than 20% serogroup C strains were Austria, Denmark, Israel, Italy, the Netherlands and Norway. All these countries had correspondingly high proportions of serogroup B strains, except for Israel where 20% of the grouped cases were attributable to serogroup Y. In previous years (since 1996), in both the Czech and Slovak Republics, serogroup C predominated. This year, for the first time since our reports began, the Czech Republic has converted to the European pattern.
Serogroup A accounted for only 0.3% of the total cases in Europe, but in Greece, Romania (small numbers) and Moscow it accounted for more than 10% of their cases. Likewise, serogroup Y comprised a small percentage of the total (1.3%), but accounted 20% of cases in Israel. England and Wales, France, Germany and the Netherlands each had more than 10 cases of serogroup W135 infection.
The case fatality rate for each serogroup varied. Serogroup A had the highest rate (14.3%) followed by W135 (10.8%), C (8.0%) and Y (4.5%). Serogroup B had the lowest rate (4.3%). 
Predominant Serotype and Strains
In the countries that provided data on serotypes (table 7) type B: 4 was the most reported overall of serogroup B, followed by B: 15. Type C: 2a was the most reported overall of serogroup C, followed by C: 2b. The country where this was not the case was Poland, where the most numerous serogroup B type was B: 22. Also the only C types isolated in Poland were C: 22 and C: 21.
The predominant serotypes of serogroups B and C are shown geographically (figure 4). Of the other serogroups only W135 and Y generated subtyped isolates in any significant number. The most reported subtypes were W135: 2a (n = 71) and Y: 14 (n = 35), and the most reported strains were W135: 2a: P1.2, 5 (n = 62) and Y: 14: P1.5 (n = 13). All the main serogroups had a predominant sero/subtype combination strain (table 7) 
Antibiotic Resistance
For this report 19 countries provided resistance data (table 9) . Eighteen countries provided data on penicillin, fifteen on rifampicin and thirteen on sulphonamide. As in the previous report, only a handful of samples in a small number of countries tested as resistant to either penicillin or rifampicin. Resistance to penicillin was only shown in five of the eighteen r eporting countries while resistance to rifampicin only appeared in one. The European figures for penicillin, rifampicin and sulphonamide resistance were similar to those for 1998/99. Thirteen countries used for total n/a no data available NB: Italy -1 case out of 18 tested showed resistance to penicillin, 0 cases out of 20 showed resistance to rifampicin and 4 cases out of 15 tested showed resistance to sulphonamide.
Lithuania -1 case out of 9 tested showed resistance to penicillin, 0 cases out of 3 showed resistance to rifampicin and 1 case out of 1 tested showed resistance to sulphonamide.
Results: Haemophilus influenzae and Pneumococcal Meningitis
Eight countries reported H. influenzae and pneumococcal meningitis case data. One country reported only H. influenzae data and one country reported only pneumococcal data. Some of the data are incomplete, as in previous years. The incidence rate for H. influenzae meningitis ranged from 0.02 in Norway to 0.70 in Slovenia. The incidence rate for pneumococcal meningitis ranged from 0.07 in Poland to 1.06 in the Netherlands. Four deaths were reported from H. influenzae meningitis (CFR 3.4%), and twenty-seven deaths were reported from pneumococcal meningitis (CFR 6.8%). Most cases of pneumococcal and H. influenzae meningitis reported by each country occurred in the 1 st and 2 nd quarters of 1999 (table 10) .
The age distribution of the H. influenzae cases showed a characteristic peak in children aged 1 to 4 years in this period. Again there was a larger percentage of cases in children aged 1 to 11 months than in the previous period. In a similar pattern to the previous period more than 75% of H. influenzae meningitis cases occurred in children less than 5 years of age (figure 5). Around two thirds of the pneumococcal meningitis cases reported occurred in adults over 24 years of age. Most of the remaining pneumococcal cases (22%) were in children aged less than 5 years (figure 6).
Twenty-six H. influenzae meningitis isolates were confirmed as type b, with 1 case each confirmed as types e, f and non-b. 182 cases of pnumococcal meningitis isolates had their serogroup confirmed. Twenty-four different serogroups were identified (figure 7). 
